MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1155/jdr/6626154

Медицинская библиотека · Journal of diabetes research · 2025

Effects of Statin Therapy on Glycemic Control and Associated Factors Among Type 2 Diabetes Mellitus Patients in Northeastern Tanzania: A Retrospective Cohort Study.

Mujuni Daniel P, Kilonzo Kajiru G, Sadiq Abid M, Kyala Norman J, Makupa Philip C, Laizer Sweetness N, Mkwizu Elifuraha W, Lyamuya Furaha S, Shao Elichilia R, Mboya Erick A, Chamba Nyasatu G

СтатьяПеревод пока не подготовлен

Аннотация

Introduction

Statins have been implicated in poor glycemic control among patients with diabetes mellitus (DM), prompting the US Food and Drug Administration (FDA) to update warning labels on all statins to reflect the risk of increased blood glucose levels. However, few studies from sub-Saharan Africa have assessed this concern. This study investigated the effects of statins on glycemic control among patients with Type 2 diabetes mellitus (T2DM) in Kilimanjaro, northeastern Tanzania. Materials and

Methods

This was a hospital-based retrospective cohort study evaluating changes in glycated hemoglobin (HbA1c) at 1-3, 7-12, and 19-24 months, as the primary outcome, comparing statin users and nonusers among T2DM patients attending DM clinic at Kilimanjaro Christian Medical Centre in Tanzania. Binomial regression models were fitted to calculate adjusted risk ratios for independent predictors of a ≥ 0.2% rise in HbA1c, with statistical significance set at p < 0.05.

Results

Out of 122 patients, 51 (41.8%) were on statin therapy. Among these, 46 (90.2%) were prescribed atorvastatin. Statin users had an increase of mean HbA1c from 10.6% ± 2.7% at baseline compared to 11.6% ± 2.8% at 1-3 months (p = 0.114), followed by a decrease to 10.1% ± 2.2% at 7-12 months (p = 1.0), and 10.0% ± 2.5% at 19-24 months (p = 1.0). However, atorvastatin users (n = 46) had a significant increase of mean HbA1c from 10.7% ± 2.8% at baseline compared to 11.9% ± 2.7% at 1-3 months (p = 0.04). In contrast, nonstatin users had a consistent and significant decrease in HbA1c from 11.3% ± 2.8% at baseline compared to 9.7% ± 2.2% at 1-3 months (p = 0.001), to 9.7% ± 2.6% at 7-12 months (p = 0.011), and to 9.3% ± 2.2% at 19-24 months (p = 0.001).

Conclusion

Statin therapy among patients with T2DM was associated with short-lived worsening of glycemic control at 1-3 months posttherapy.

Для цитирования: Mujuni Daniel P, Kilonzo Kajiru G, Sadiq Abid M, Kyala Norman J, Makupa Philip C, Laizer Sweetness N, Mkwizu Elifuraha W, Lyamuya Furaha S, Shao Elichilia R, Mboya Erick A, Chamba Nyasatu G. Effects of Statin Therapy on Glycemic Control and Associated Factors Among Type 2 Diabetes Mellitus Patients in Northeastern Tanzania: A Retrospective Cohort Study.. Journal of diabetes research. 2025. DOI: 10.1155/jdr/6626154.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.